There is a growing body of research demonstrating that an individual’s metabolic ‘biosignature’, measured through nuclear magnetic resonance (NMR*) spectroscopy, can possibly provide reliable insight for researching into the severity of COVID-19 disease, patient progress towards recovery, and individual risk of developing Post-Acute COVID Syndrome (PACS), also known as ‘long COVID’.
Researchers at the Australian National Phenome Centre (ANPC), Murdoch University, previously described the concept of phenoconversion — the change from a normal or healthy state to a disordered pathophysiological state or overt pathology — characterized by a series of rapid localized and systemic effects in metabolism and physiology. A range of metabolic biomarkers that are specific to disease state detection and measurement of severity can be analyzed, and results from NMR* measurements on plasma has the potential to provide researchers with deep insights into a range of pathophysiological processes.
This white paper reviews several key publications that have identified biomarkers of metabolic changes associated with PACS. These studies have led to a more advanced understanding of how a person’s metabolic phenotype can influence their likelihood of developing PACS and, eventually, contribute to better patient outcomes.
*Bruker NMR Instruments are for Research Use Only. Not for Use in Clinical Diagnostic Procedures
In this white paper, we review 13 publications, and you can learn how,